AAV2-GDNF ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04167540 (ClinicalTrials.gov)	April 1, 2020	7/11/2019	GDNF Gene Therapy for Parkinson's Disease	Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in ...	Parkinson's Disease	Biological: AAV2-GDNF	Brain Neurotherapy Bio, Inc.	Asklepios Biopharmaceutical, Inc.;California Institute for Regenerative Medicine (CIRM)	Active, not recruiting	35 Years	75 Years	All	11	Phase 1	United States
2	NCT01621581 (ClinicalTrials.gov)	March 13, 2013	14/6/2012	AAV2-GDNF for Advanced Parkinson s Disease	A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Ass ...	Parkinson's Disease	Genetic: Convection enhanced delivery/AAV2-GDNF	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Completed	18 Years	N/A	All	25	Phase 1	United States

First Previous1Next Last